Screener
Eton Pharmaceuticals, Inc. ETON Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Eton Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-017064
| Line item | For the three months ended / March 31, 2026 | For the three months ended / March 31, 2025 |
|---|---|---|
| Research and development | 1,875 | 1,161 |
| General and administrative | 10,446 | 9,170 |
| Total operating expenses | 12,321 | 10,331 |
| Income (loss) from operations | 2,414 | (470) |
| Other expense: | ||
| Interest and other expense, net | (840) | (1,028) |
| Income (loss) before income tax expense | 1,574 | (1,498) |
| Income tax expense | 20 | 74 |
Document
FAQ
- What is Eton Pharmaceuticals, Inc.'s operating income?
- Eton Pharmaceuticals, Inc. (ETON) reported operating income of $2.41M in Q1 2026.
- How has Eton Pharmaceuticals, Inc.'s operating income changed year-over-year?
- Eton Pharmaceuticals, Inc.'s operating income increased by 613.6% year-over-year, from -$470K to $2.41M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Eton Pharmaceuticals, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude